Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children

被引:18
|
作者
Wasilewska, Anna M. [1 ]
Zoch-Zwierz, Walentyna M. [1 ]
机构
[1] Med Univ Bialystok, Dept Pediat & Nephrol, PL-15274 Bialystok, Poland
关键词
children; cyclosporine A; MMP2; MMP9; nephrotic syndrome; TIMP1; TIMP2;
D O I
10.1007/s00467-008-0881-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS). The study group (1) consisted of 18 children SDNS aged 3.5-17.0 years treated with CyA. All NS children were examined three times: (A) at proteinuria relapse, before CyA treatment, (B) after 6 months, and (C) after 12 months of CyA administration. The control group (2) consisted of 18 healthy children. Serum CyA level was assessed by immunofluorescence. Enzyme-linked immunosorbent assay kits for total human MMP2 and 9 and TIMP1 and 2 were obtained from R&D Systems. Compared with healthy controls, urinary MMP9/Cr in NS children before CyA was on the same level and increased during CyA treatment, and urinary TIMP1/Cr was twice as high and increased significantly during CyA treatment. MMP9/TIMP1 in NS children treated with CyA increased, but the difference was not statistically significant. Urinary MMP2/Cr was similar, and urinary TIMP2/Cr was significantly higher in children treated with CyA (p < 0.01). The MMP2/TIMP2 ratio in NS children treated with CyA was significantly lower in comparison with healthy controls (p < 0.01). A negative correlation was noted between urinary MMP2/TIMP2 ratio and serum CyA in NS children (r=-0.541, p < 0.01). An imbalance within the MMP2 and TIMP2 and MMP9 and TIMP1 system may play a role in the pathogenesis CyA nephropathy.
引用
收藏
页码:1795 / 1802
页数:8
相关论文
共 50 条
  • [21] Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
    Borden, P
    Heller, RA
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2): : 159 - 178
  • [22] Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases
    Klaus Maskos
    Wolfram Bode
    Molecular Biotechnology, 2003, 25 : 241 - 266
  • [23] Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases
    Maskos, K
    Bode, W
    MOLECULAR BIOTECHNOLOGY, 2003, 25 (03) : 241 - 266
  • [24] Balance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
    Yalcinkaya, Emre
    Celik, Murat
    CARDIOLOGY, 2014, 128 (04) : 316 - 316
  • [25] Matrix metalloproteinases and tissue inhibitors of metalloproteinases in ovarian function
    McIntush, EW
    Smith, MF
    REVIEWS OF REPRODUCTION, 1998, 3 (01): : 23 - 30
  • [26] MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN HUMAN GLIOMAS
    NAKANO, A
    TANI, E
    MIYAZAKI, K
    YAMAMOTO, Y
    FURUYAMA, JI
    JOURNAL OF NEUROSURGERY, 1995, 83 (02) : 298 - 307
  • [27] Tissue inhibitors of matrix metalloproteinases in cancer
    Blavier, L
    Henriet, P
    Imren, S
    DeClerck, YA
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 108 - 119
  • [28] Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases
    Bode, W
    Maskos, K
    BIOLOGICAL CHEMISTRY, 2003, 384 (06) : 863 - 872
  • [29] Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in malignant lymphoma
    Lee, AW
    Lee, AH
    Lee, KY
    Kang, CS
    Shim, SI
    Kim, BK
    MODERN PATHOLOGY, 2002, 15 (01) : 250A - 250A
  • [30] Matrix metalloproteinases and their tissue inhibitors in endocrinology
    Salamonsen, LA
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1996, 7 (01): : 28 - 34